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Abstract. Gammacarboxyglutamate (Gla) is an uncommon
amino acid formed by vitamin K action. Increasing evidence
indicates that Gla-proteins are involved in the regulation of
calcification processes in both bone tissue and atheroscle-
rotic vessel wall. In a population-based study we have pre-
viously shown that in a group of 113 postmenopausal
women the presence of abdominal aortic calcifications is
associated with a reduced vitamin K status. In the present
study we investigated whether this reduced vitamin K status
was also associated with differences in bone mass or circu-
lating calciotropic hormone levels. Serum immunoreactive
osteocalcin with low affinity for hydroxyapatite (irOCfree)
was used as a marker for vitamin K status. After correction
for age it was found that women with atherosclerotic calci-
fications had a 7% lower bone mass as measured by meta-
carpal radiogrammetry (mean difference: 3.2 mm2, 95% CI:
−0.2–6.5, P 4 0.06). No differences between both groups
of women were observed for serum intact parathyroid hor-
mone (PTH) and serum 25-hydroxyvitamin D levels. In the
atherosclerotic women (n 4 34), markers for vitamin K
status were inversely associated with bone mass (r 4 −0.47,
P 4 0.013), whereas no such association was found in the
nonatherosclerotic women (n 4 79). It is concluded that the
atherosclerotic women in this study may be at higher risk
for osteoporotic fractures as evidenced by their lower bone
mass and higher serum irOCfree levels. The finding that in
atherosclerotic women vitamin K status is associated with
bone mass supports our hypothesis that vitamin K status
affects the mineralization processes in both bone and in
atherosclerotic plaques.
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Osteoporosis and atherosclerosis are two major chronic
causes of morbidity. Although they tend to be regarded as
two independent, age-related processes, it is striking that in
women the prevalence of both disorders increases dramati-
cally after menopause [1]. Estrogen deficiency or a derange-
ment in calcium metabolism have been proposed as candi-
dates for common pathophysiological factors [2–4].
Results from recent studies suggest that atherosclerotic
calcification must be regarded as a highly regulated process
similar to that occurring in bone tissue [5]. It is of interest
that in both calcification processes vitamin K-dependent
proteins are thought to be involved [6–9]. Vitamin K-
dependent proteins have calcium-binding properties medi-
ated by the posttranslationally acquired g-carboxyglutamate
(Gla) residues [10]. A diminished availability of vitamin K,
e.g., due to a reduced nutritional intake or impaired intes-
tinal absorption, may result in a decreased Gla-content of
the various Gla-proteins. In the latter case, Gla-proteins,
such as osteocalcin, will be functionally defective resulting
in a reduced affinity for the hydroxyapatite bone matrix.
This can be measured in serum as the serum immunoreac-
tive osteocalcin with a low affinity for hydroxyapatite
(irOCfree) [11]. The high affinity osteocalcin (irOCbound),
expressed as a percentage of total serum osteocalcin, is
called the hydroxyapatite-binding capacity of osteocalcin
(HBC) and is regarded as a measure for osteocalcin Gla-
content and for vitamin K status [12–14]. Since the corre-
lation between circulating vitamin K and tissue vitamin K is
unclear at this time, undercarboxylated Gla-proteins form a
unique tool to assess the vitamin K status in the tissues from
which these proteins originate.
It has been suggested that even a mild vitamin K defi-
ciency may affect calcium homeostasis. In a number of
trials, we have recently shown that markers of bone forma-
tion increase, whereas bone resorption markers decrease
with the administration of pharmacological doses of vitamin
K [12–14]. These data are consistent with two Japanese
studies, both of which demonstrated that vitamin K supple-
mentation may retard postmenopausal loss of bone mass
[15, 16]. We have recently shown that in a group of post-
menopausal women, the presence of atherosclerotic calcifi-
cations in the abdominal aorta, considered to be a strong
predictor of cardiovascular heart disease and mortality [17–
19], is associated with a marginal vitamin K status [20]. In
the present study we examined whether the reduced vitamin
K status in the atherosclerotic women was associated with a
reduced bone mass as well.
Materials and Methods
Subjects
Participants were selected from a population-based study on de-
terminants of osteoporosis and atherosclerosis [21]. Bone massCorrespondence to: C. Vermeer
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measurements as well as the extent of calcified deposits in the
abdominal aorta were determined in 1985. In 1990, 256 women
consented to take part in a follow-up examination [20]. In brief,
aortic calcification (grade 3 or grade 4) was found to be present in
34 subjects. Seventy-nine women without aortic calcification
(grade 0) were randomly selected from the cohort. Subjects using
vitamin K antagonists were excluded.
Abdominal Aorta Calcification
Atherosclerosis of the abdominal aorta was assessed using a lateral
X-ray film of the lumbar spine (T12-S1), from which the presence
of calcified deposits was determined [22]. The severity of the
atherosclerosis was graded from 0 (no calcifications) to 4 (aorta
outlined with calcifications) [20].
Bone Mass
Bone mass measurements was determined using metacarpal radio-
grammetry. The outer diameter (D) and medullar diameter (d)
were measured at the midshaft of the metacarpal bones, using a 7
times magnifying measurement loop with an accuracy of 0.01 mm.
Bone mass (metacarpal cortical area) was expressed as the mean
value of D2-d2 (mm2) of the metacarpal bones II, III, and IV of
both hands. The mean intra-individual standard deviation (SD) of
a duplicate measurement was 1.9 mm2 (4%), which is in accor-
dance with previous reports [23].
Anthropometric Variables
Height and weight were measured without shoes and with indoor
clothing. The body mass index (kg/m2, BMI) was calculated. The
circumferences of the waist and hip were measured and the waist-
to-hip ratio (WH-ratio) was calculated.
Vitamin K Status
Immediately after preparation, the nonfasting serum and plasma
samples were frozen at −80°C. Serum immunoreactive osteocalcin
(irOC) levels were measured before (irOCtotal) and after (irOCfree)
extraction with 100 mg/ml hydroxyapatite [12]. Serum irOCbound
was calculated from the difference between irOCtotal and irOCfree.
The HBC was calculated as the percentage of irOCbound relative to
the total serum irOC level and used as an overall estimate of the
Gla-content of circulating irOC levels. In young, healthy adults,
the HBC values range between 70 and 80%; decreased values are
found in subjects with a marginal vitamin K status [12, 13]. Inter-
and intraassay coefficients of variation of serum irOCtotal were
10% and 5%, respectively.
Additional Measurements
Serum intact parathyroid hormone levels (iPTH) were measured
with a direct immunoradiometric assay (IRMA) (N-tactt) PTH
SP) and serum 25-hydroxyvitamin D (250HD) levels were deter-
mined using radioimmunoassay (RIA) (both obtained from Incstar,
Stillwater, MI).
Data Analysis
Multiple linear regression was used for analysis of differences
across groups with and without atherosclerosis, adjusted for con-
founding variables such as age. The differences are presented with
a 95% confidence interval (95% CI). Analyses were performed
using the BMDP statistical package. Results are presented as the
mean values (± SD) unless indicated otherwise.
Results
As reported previously, no major differences were noted
between the women with or without atherosclerosis with
respect to their age (67.8 ± 5.5 and 66.1 ± 4.1, respectively),
BMI 25.4 ± 3.2 and 26.5 ± 3.0 kg/m2, respectively), or
WH-ratio (0.84 ± 0.05 and 0.84 ± 0.06, respectively) [20].
The atherosclerotic women had higher serum total choles-
terol levels (7.56 ± 1.05 mmol/liter) compared with the
nonatherosclerotic women (6.85 ± 1.00 mmol/liter, P <
0.01), whereas no difference was noted in their serum HDL-
cholesterol levels (1.84 ± 0.65 and 1.74 ± 0.94 mmol/liter,
respectively).
The bone mass of the atherosclerotic and nonatheroscle-
rotic women was 41.6 and 45.1 mm2, respectively, consti-
tuting a mean difference of 3.5 mm2 (95% CI: −6.7, −0.2) or
8% (P 4 0.04) (Table 1). Adjustment for age slightly at-
tenuated the difference to −3.2 mm2 (95% CI: −6.5, 0.2 P4
0.06). In the atherosclerotic women, bone mass was signifi-
cantly associated with both serum irOCfree (r 4 −0.47, P 4
0.013) and HBC levels (r 4 0.57, P4 0.002) (Table 2). No
such associations were found in the women without athero-
sclerosis (Table 2). Adjustment for age, BMI, or serum
cholesterol did not essentially alter these findings (data not
shown).
No differences were observed in serum iPTH and
250HD levels (Table 1). Serum 250HD levels of 12 ng/liter
(considered as borderline value) and lower were present in
44% of the women [24, 25]. In both the atherosclerotic and
nonatherosclerotic women, bone mass was positively asso-
ciated with serum 250HD levels (pooled data: r 4 0.23, P
Table 1. Parameters tested in postmenopausal women with and without calcifications of the abdominal aorta
Aortic calcifications
Absent Present Mean difference P-value Age adj. difference P-value
Number 79 34
irOCfree(ng/ml) 1.93 (0.08) 2.16 (0.15) 0.23 [−0.07, 0.53] 0.14 0.32 [0.03, 0.61] 0.04
HBC (%) 59.4 (0.98) 54.6 (1.77) −4.79 [−8.49, −1.09] 0.01 −5.12 [−8.92, −1.32] 0.01
Bone mass (mm2) 45.1 (0.9) 41.6 (1.4) −3.5 [−6.7, −0.2] 0.04 −3.2 [−6.5, 0.2] 0.06
iPTH (pg/ml) 41.6 (1.8) 43.7 (2.8) 2.1 [−4.2, 8.4] 0.52 2.0 [−4.4, 8.5] 0.54
25OHD (ng/ml) 15.4 (1.6) 16.8 (1.6) 1.4 [−3.1,5.8] 0.07 1.8 [−2.5, 6.2] 0.41
Values are given as means with standard errors. (in parentheses) and 95% confidence intervals [in brackets]
Abbreviations: irOCfree 4 serum immunoreactive osteocalcin free; HBC 4 hydroxyapatite-binding capacity of serum osteocalcin; iPTH
4 intact serum PTH; 250HD 4 serum 25-hydroxyvitamin D
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4 0.07), but not with serum iPTH (pooled data: r 4 0.10,
P 4 0.36) (Table 2). Serum iPTH levels were significantly
associated with serum irOCfree (pooled data: r 4 0.30, P 4
0.002) and HBC (pooled data: r 4 −0.27, P4 0.005) levels
in both groups. The associations remained essentially un-
changed after additional adjustments for possible confound-
ers as age, BMI, and serum cholesterol levels.
Discussion
The results of our study indicate that in postmenopausal
women the presence of atherosclerotic calcifications in the
abdominal aorta is not only associated with a marginal vi-
tamin K status [20], but also with a low bone mass. In
comparisons of necropsy with computed tomography find-
ings, atherosclerotic calcifications in the abdominal aorta
have previously been shown to represent severe aortic ath-
erosclerosis [26, 27]. These calcifications have shown to be
strong predictors of coronary heart disease [28, 29] and
cardiovascular mortality [18, 19, 28]. Assessment of bone
mass by radiogrammetry based on multiple measurements
of six metacarpal bones, on the other hand, has been shown
to be sufficiently precise for meaningful comparisons of
bone density between individuals [21, 23].
Low bone mass is a well established and important risk
factor for the development of osteoporotic fractures [30,
31]. Recent data strongly indicate that high serum irOCfree
levels are associated with an increased risk for hip fractures
[32] and that in elderly women, elevated serum irOCfree
levels are associated with a low bone mass [33]. The find-
ings of our study that atherosclerotic women had a low bone
mass and high irOCfree levels therefore strongly suggest that
they are at increased risk for developing osteoporotic frac-
tures.
Several studies have reported that both low bone mass
and increased frequency of osteoporotic fractures are asso-
ciated with atherosclerotic calcifications [2, 3, 34–37] or
cardiovascular deaths [4, 38]. Some have regarded the ob-
served associations merely as being age-related phenomena
[35, 36], whereas others have suggested a causal relation-
ship [2, 3, 34, 38]. High serum levels of iPTH or 250HD
have been proposed as causally related factors, however,
this is not supported by our data. The 250HD and iPTH
serum levels in our study are in accordance with other stud-
ies performed in The Netherlands [24, 25]. The relatively
high serum iPTH levels in our study population are indica-
tive of a secondary hyperparathyroidism commonly found
in women of this age [25, 39]. The finding that serum iPTH
is associated with serum irOCfree levels suggests that serum
irOCfree may result from PTH-mediated bone resorption[40]. Although it is assumed that serum irOCfree consists of
undercarboxylated osteocalcin, there is some evidence that
at least part of the circulating irOCfree is formed by dena-
tured osteocalcin or osteocalcin degradation products, pos-
sibly originating from bone resorption [14, 40].
Accumulating evidence suggests that vitamin K stimu-
lates bone formation and inhibits bone resorption which
ultimately may lead to a decrease in bone loss [12–16]. The
fact that only in the atherosclerotic women both markers for
vitamin K status were strongly associated with bone mass
suggests that additional (as yet unknown) factors may be of
importance. It has been suggested for instance that abnor-
malities in lipoprotein metabolisms may influence vitamin
K transport to bone tissue [41].
The question remains What may be the pathophysiologi-
cal mechanism in which a reduced vitamin K status leads to
a lower bone and an increased frequency of atherosclerotic
calcifications. Recent evidence strongly supports the con-
cept that the calcification associated with atherosclerosis
must be regarded as an active, highly organized process
similar to that of osteogenesis [5, 42]. Gla-proteins appear
to be involved in both processes [6, 8, 9]. The Gla-proteins
MGP (matrix Gla-protein) and osteocalcin are both in-
volved in the bone mineralization process. Their exact func-
tion, however, is still unclear. Recently, high levels of MGP
mRNA and protein were demonstrated in macrophages and
in vascular smooth muscle cells, present in human athero-
sclerotic plaques [9]. This strongly suggests that MGP
found in the plaques is not absorbed from the blood stream,
but that it is produced locally at the site of these plaques. We
speculate that the function of vascular MGP is similar to
that in bone [43], i.e., that it acts as a mineralization inhibi-
tor. By analogy with the fetal warfarin syndrome [44], un-
dercarboxylation of MGP would thus be a risk factor for
excessive mineralization of the atherosclerotic vessel wall.
Osteocalcin, on the other hand, is predominantly synthe-
sized by the more differentiated osteoblast, relatively late in
bone development, concomitant with or after the onset of
mineralization [45]. Also, its different molecular properties
and tight association with the mineral matrix suggest a dif-
ferent function for osteocalcin, for instance, in bone remod-
eling or in the accumulation of bone mass [46]. In mature
bone tissue, a suboptimal vitamin K status might thus affect
the osteocalcin-mediated remodeling process ultimately
leading to a net loss of bone mass [12–16].
In conclusion, we found that the presence of atheroscle-
rotic calcifications in postmenopausal women is associated
Table 2. Correlations tested in postmenopausal women with and without calcifications of the
abdominal aorta
Correlations tested
Aortic calcif. absent Aortic calcif. present Pooled data
r (p-value) r (p-value) r (p-value)
Bone mass - irOCfree 0.12 (0.33) −0.47 (0.013)
Bone mass - HBC −0.14 (0.28) 0.57 (0.002)
Bone mass - 25OHD 0.23 (0.07)
Bone mass - iPTH 0.10 (0.36)
iPTH - irOCfree 0.30 (0.01) 0.39 (0.03) 0.30 (0.002)
iPTH - HBC −0.27 (0.02) −0.21 (0.05) −0.27 (0.005)
Abbreviations: r 4 correlation coefficient. For other abbreviations see Table 1; where cor-
relations were ommitted, no significance was observed
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with an impaired vitamin K status as well as a low bone
mass. These findings support the view that aortic calcifica-
tion and bone loss may be two related processes, with vi-
tamin K deficiency as a common denominator. Further stud-
ies are needed to investigate the potential benefit of vitamin
K supplementation.
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